SELLAS Life Sciences Group, Inc. (SLS): Cash & Equivalents
$71.79M
As of 2025-12-31
$138.34M
As of 2026-06-30
+61.2%
3-year compound annual growth
+15.3%
5-year compound annual growth
+9.2%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.79M | +417.0% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $13.89M | +448.9% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $2.53M | -85.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $17.12M | -19.8% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $21.36M | -39.5% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $35.30M | +385.1% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $7.28M | +36.4% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $5.34M | +130.1% | 2020-03-13, Balance as of period end |
| 2017-12-31 | $2.32M | -61.1% | 2019-03-22, Balance as of period end |
| 2016-12-31 | $5.96M | -79.9% | 2018-04-13, Balance as of period end |
| 2015-12-31 | $29.73M | +25.7% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $23.65M | -50.5% | 2017-03-15, Balance as of period end |
| 2013-12-31 | $47.79M | +45.7% | 2016-04-15, Balance as of period end |
| 2012-12-31 | $32.81M | +187.0% | 2015-03-05, Balance as of period end |
| 2011-12-31 | $11.43M | +65.9% | 2014-03-17, Balance as of period end |
| 2010-12-31 | $6.89M | n/a | 2012-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | 2025-12-31 | $71.79M | +417.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $3.04M | +39.8% |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $44.27M | -32.7% |
| Incannex Healthcare Inc. (IXHL) | 2026-06-30 | $67.71M | +350.2% |
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $6.66M | n/a |
| Aldeyra Therapeutics, Inc. (ALDX) | 2025-12-31 | $70.04M | +28.5% |
| Eupraxia Pharmaceuticals Inc. (EPRX) | 2025-12-31 | $80.56M | +143.4% |
Compare SLS, ADAG, CPIX, NWBO side by side · Screen every company in Pharmaceutical Preparations ↗